The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

A device for endovascular treatment to ameliorate aneurysm recurrences by deploying a treatment mesh having a plurality of vertically oriented elongated support reinforcement elements that are substantially parallel and oriented upon a plane in communication with the mesh. Upon deployment, the array of distal ends of the support extensions and reinforcements are substantially oriented upon a plane, which plane is in substantially the same orientation as the opening of the aneurysm into which the device was deployed. The treatment mesh may incorporate a coating of hydrogel, optionally impregnated with pharmaceutical compounds.

An implantable device, including: a tube including a plurality of biodegradable biometallic wires braided together, the tube being coated with a flexible conformal biodegradable polymer in an expanded state such that, upon compression and release of compression, the flexible conformal biodegradable polymer-coated tube self-expands back to the expanded state.

Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here.

The present invention is an embolization coil having an optimum morphological stability. The embolization coil includes a wire material made of an Au—Pt alloy. The wire material constituting the embolization coil has such a composition that a Pt concentration is 24 mass % or more and less than 34 mass %, with the balance being Au. The wire material has such a material structure that a Pt-rich phase of an Au—Pt alloy having a Pt concentration of 1.2 to 3.8 times a Pt concentration of an α phase is distributed in an α phase matrix. The wire material has a bulk susceptibility of −13 ppm or more and −5 ppm or less. In a material structure of a transverse cross-section of the wire material, an average value of two or more average crystal particle diameters measured by a linear intercept method is 0.20 μm or more and 0.35 μm or less.

The present invention relates to a medical Au-Pt-Pd alloy including Au, Pt,Pd, and inevitable impurities. The Au-Pt-Pd alloy has an alloy compositioninside a polygon (A1-A2-A3-A4) surrounded by straight lines connected at pointA1 (Au: 53 atom%, Pt: 4 atom%, and Pd: 43 atom%), point A2 (Au: 70 atom%,Pt: 4 atom%, and Pd: 26 atom%), point A3 (Au: 69.9 atom%, Pt: 30 atom%, and Pd: 0.1 atom%), and point A4 (Au: 49.9 atom%, Pt: 50 atom%, and Pd: 0.1 atom%) in a Au-Pt-Pd ternary state diagram. In a metal structure of the alloy, at least one of a Au-rich phase and a Pt-rich phase is distributed, and the total of the area ratio of the Au-rich phase and the area ratio of the Pt-rich phase is 1.5% or more and 25.4% or less.

The present disclosure is directed to a medical device for inhibiting the activity of bacterial collagenase and/or a matrix metalloproteinase (MMP). In some embodiments, the medical device comprises a polymer that includes a transition metal or a salt thereof. In some embodiments, the medical device comprises an alloy that has at least one of a transition metal or a transition metal salt.

A medical device includes a substrate structure with a surface. The surface is laser treated to define at least one protrusion and/or at least one void extending relative to the surface. A coating having antibacterial, antimicrobial and/or drug eluding properties is applied to the substrate structure such that the coating engages within or along a surface portion of one or more of the protrusions and/or voids.

An absorbable implantable medical device made of iron-based alloy, including a base made of iron-based alloy and a complex, wherein the complex includes a complexing agent. In a physiological solution, the base made of iron-based alloy can react with the complexing agent to generate a water-soluble iron complex having solubility in the physiological solution of no less than 10 mg/L. A corrosion product generated after the absorbable implantable medical device made of iron-based alloy is implanted in a human body can be quickly metabolized/absorbed by the body.

A vaso-occlusive device is constructed out of dissimilar metallic materials that are in contact or otherwise in close proximity with one another, thereby causing the device to undergo galvanic corrosion when exposed to an electrolytic medium, such as blood or other body fluid, wherein one of the dissimilar metallic materials is zirconium or zirconium alloy to create a corrosive product including zirconia having a relatively high hardness, a relatively high fracture toughness, and a relatively high stability when the device is implanted in a vasculature site, such as an aneurysm.